Parasite Antigens Ease Colitis via Gut Microbiome Shift

Scientists have found that antigens derived from the parasitic worm Paragonimus proliferus can significantly reduce the severity of ulcerative colitis (UC) in mice, while also reconfiguring the gut microbiome, according to a study published in PLOS Neglected Tropical Diseases on 13 May 2026. The findings add to a growing body of microbiome UK and global research suggesting that helminth-derived molecules may offer a new avenue for treating inflammatory bowel disease.

Why This Matters

Ulcerative colitis affects hundreds of thousands of people in the UK, placing a considerable burden on NHS gut health services and patients' quality of life. Current treatment options remain limited, and a significant proportion of patients do not achieve sustained remission with existing therapies. Gut health UK researchers and clinicians are increasingly looking beyond conventional pharmaceuticals, with UK microbiome research — including work at institutions such as King's College London and the University of Oxford — highlighting how the balance of gut bacteria plays a central role in regulating intestinal inflammation.

Parasite-Derived Antigens Reduce Colitis Severity

The study, led by Lei Zhang and colleagues, used a dextran sulfate sodium (DSS)-induced mouse model of UC to test the effects of Paragonimus proliferus metacercaria-derived antigens (PmAg). Intraperitoneal delivery of PmAg substantially mitigated colitis severity, as demonstrated by decreased weight loss, lower disease activity index scores, maintained colon length, and improved histopathological findings, the researchers report. The team found that PmAg worked through immunomodulation — dampening harmful inflammatory responses — and by reconfiguring the composition of the gut microbiota, per the published findings.

What This Means for Gut Health Research

The results support the broader scientific hypothesis that parasitic helminths, having co-evolved with mammalian hosts over millennia, have developed sophisticated strategies to modulate host immune responses. This gut-brain connection between immune signalling and microbial balance is of particular interest to UK microbiome researchers exploring how to improve gut health naturally in people with inflammatory conditions. The study's authors suggest that helminth-derived antigens could represent a safer alternative to live parasite-based therapies, which have faced practical and ethical hurdles in clinical settings.

For UK patients and clinicians, the research underscores why the microbiome is now considered a primary therapeutic target in inflammatory bowel disease. Bodies such as the British Dietetic Association and the British Nutrition Foundation have long emphasised dietary fibre and microbiome diversity as pillars of gut health; this study adds a novel immunological angle to that picture.

While the research remains at the preclinical stage and was conducted in mice, the mechanistic insights — linking parasite-derived molecules, immune regulation, and microbiota reconfiguration — offer a compelling direction for future clinical investigation. Researchers and NHS gut health specialists will be watching closely as the science develops.

You might also like

• Children's Gut Health and Immunity: What Parents Should Know
• Your Gut Microbiome & Psychedelic Therapy
• Gut Bacteria and Obesity: How Microbiome Affects Weight

96 Bacterial Strains. Two Shots a Day.

GOODIE is an award-winning fermented drink with 96 live bacterial strains — more than any yogurt or kombucha — never pasteurised, clinically tested, and 8 in 10 users felt less bloating within 14 days. Curious?

Find out more →